



Arnold B. Calmann
(973) 645-4828
abc@saiber.com

February 23, 2023

BY ECF

Honorable Jessica S. Allen, U.S.M.J.
United States District Court for the District of New Jersey
Martin Luther King Jr. Bldg. & U.S. Courthouse
50 Walnut Street
Newark, New Jersey 07102

**Re: *Mylan Pharms. Inc. v. Teva Pharms. Indus. Ltd., et al.*,
Civil Action No. 2:21-13087 (JXN) (JSA)**

Dear Judge Allen:

Mylan Pharmaceuticals Inc. ("Plaintiff"), and Teva Pharmaceuticals Industries Ltd., Teva Pharmaceuticals, Inc., Teva Neuroscience, Inc., and Teva Sales & Marketing ("Defendants" or "Teva") collectively ("the Parties"), submit this joint status letter in accordance with the Court's February 14, 2023 Order. ECF No. 109.

Phase 1 Productions Completed

Since the filing of the Parties' January 9, 2023 joint status letter, Mylan produced the two additional documents on January 27, 2023 that were requested by Teva, thus concluding Phase 1 discovery.

If Your Honor desires, the Parties will be available to address these issues at Your Honor's convenience.

Respectfully submitted,

/s Arnold B. Calmann

Arnold B. Calmann

cc: Counsel of Record (by ECF & email)